Edition:
United Kingdom

XOMA Corp (XOMA.OQ)

XOMA.OQ on NASDAQ Stock Exchange Global Market

33.28USD
23 Jan 2018
Change (% chg)

$-0.56 (-1.65%)
Prev Close
$33.84
Open
$33.75
Day's High
$34.02
Day's Low
$33.23
Volume
34,573
Avg. Vol
59,226
52-wk High
$37.25
52-wk Low
$3.99

Latest Key Developments (Source: Significant Developments)

XOMA Announces Exclusive License Agreement For XOMA 358 With Rezolute Inc.
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - XOMA Corp ::XOMA ANNOUNCES EXCLUSIVE LICENSE AGREEMENT FOR XOMA 358 WITH REZOLUTE, INC..XOMA CORP - UNDER LICENSE AGREEMENT, CO IS ENTITLED TO RECEIVE UP TO APPROXIMATELY $240 MILLION IN EXCHANGE FOR GLOBAL XOMA 358 RIGHTS.XOMA CORP - TO RECEIVE PAYMENTS AS REZOLUTE ACHIEVES SPECIFIC MILESTONES ASSOCIATED WITH FINANCING ACTIVITIES, CLINICAL DEVELOPMENT SUCCESS​, OTHERS.XOMA-‍TERMS OF AGREEMENT INCLUDE ALLOCATION OF $5 MILLION IN SHARES OF REZOLUTE TO CO,$13 MILLION IN CASH,STOCK TO BE PAID AS REZOLUTE COMPLETES SOME MILESTONES​.XOMA SAYS IS ALSO ENTITLED TO RECEIVE LOW SINGLE-DIGIT ROYALTIES ON NET SALES OF AB101, OTHER PRODUCTS DEVELOPED FROM CERTAIN OF REZOLUTE PLATFORMS.XOMA CORP - REZOLUTE IS RESPONSIBLE FOR ALL DEVELOPMENT, REGULATORY, MANUFACTURING AND COMMERCIALIZATION ACTIVITIES UNDER LICENSE.XOMA SAYS REZOLUTE PLANS TO ADVANCE XOMA 358'S CLINICAL DEVELOPMENT IN 2018.XOMA CORP - ELIGIBLE TO RECEIVE ROYALTIES RANGING FROM HIGH SINGLE-DIGITS TO MID-TEENS ON NET SALES OF XOMA 358.  Full Article

Xoma posts Q3 revenue of $36.2 million
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Xoma Corp :Xoma reports third quarter 2017 financial results.Q3 revenue $36.2 million versus $600,000.Q3 revenue view $690,000 -- Thomson Reuters I/B/E/S.Qtrly diluted net income per share available to common stockholders $1.98.  Full Article

Xoma reports Q2 2016 achievements and financial results
Wednesday, 3 Aug 2016 

Xoma Corp : Q2 revenue view $903,000 -- Thomson Reuters I/B/E/S . Xoma reports second quarter 2016 achievements and financial results . Q2 revenue $400,000 versus $2.5 million .Xoma Corp says expects its available capital will be sufficient to fund operations through at least Q1 of 2017..  Full Article

Xoma wins EU "orphan drug" status for hyperinsulinism drug
Wednesday, 20 Jul 2016 

Xoma Corp : Xoma 358 is in phase 2 development for chi with clinical sites in united states and european union (eu) actively enrolling patients .Xoma receives orphan drug designation in the european union for xoma 358 for treatment of congenital hyperinsulinism.  Full Article

BRIEF-XOMA Announces Exclusive License Agreement For XOMA 358 With Rezolute Inc.

* XOMA ANNOUNCES EXCLUSIVE LICENSE AGREEMENT FOR XOMA 358 WITH REZOLUTE, INC.